The patent discloses BSN-liposomes engineered for simultaneous cancer diagnosis and therapy. These nanoscale liposomes integrate a novel fluorescent dye, BSN, enabling precise real-time imaging of cancer cells with high sensitivity and specificity. The technology leverages photothermal therapy, utilizing the same BSN-liposomes to selectively ablate cancerous tissues upon NIR irradiation, offering a minimally invasive treatment modality with potential for reduced side effects and improved patient outcomes.
Type of IP
Category of Patent
- Improved Cancer Diagnosis through fluorescence imaging contributes to early diagnosis and potentially higher survival rates.
- Enhanced Treatment Options: Integration of photothermal therapy offers a non-invasive alternative with reduced side effects compared to traditional methods.
- Economic Benefits: Efficiency gains in diagnosis and treatment could reduce healthcare costs associated with cancer care, benefiting healthcare systems and patients alike.
- Targeted Treatment: Improved delivery and localized treatment of cancer, minimizing systemic side effects
- Real-Time Monitoring: Enables simultaneous imaging and treatment, enhancing precision and effectiveness
- Biocompatibility: The theranostic complex shows efficient cellular internalization, stability, and photothermal efficacy.
- Versatility: Can be combined with other therapeutic agents like anti-inflammatory drugs, antiallergens, immunosuppressants, and corticosteroids for enhanced treatment efficacy
4
- Demonstrated high biocompatibility with >90% cell viability
- Effective fluorescence imaging in cancer cell lines, indicating strong potential for real-time diagnosis and therapy
- Proven potential for dual-use in real-time cancer detection and photothermal therapy.
- Ready for further preclinical and clinical evaluations for breast cancer treatment applications
Medical Diagnostics and Treatment, Oncology, Nanomedicine
Cancer diagnosis, imaging and targeted therapy, particularly for breast cancer.